1227156-72-0

1227156-72-0 structure

Name: Amelparib
Chemical Name: Amelparib
CAS Number: 1227156-72-0
Molecular Formula: C₁₉H₂₅N₃O₃
Molecular Weight: 343.420
Create Date: 2020-01-12 17:50:49
Modify Date: 2024-01-06 18:00:44
Amelparib (JPI-289, JPI289) is a novel potent, water soluble PARP-1 inhibitor with IC50 of 18.5 nM, inhibits cellular PAR formation with IC50 of 10.7 nM; does not affect cell viability up to 1 mM in rat cortical neuronal cells; attenuates PARP activity restores ATP and NAD+ levels in oxygen glucose deprived (OGD) rat cortical neurons, reduces apoptosis-associated molecules such as apoptosis inducing factor (AIF), cytochrome C and cleaved caspase-3 in the OGD model; JPI-289 is a potential neuroprotective agent which could be useful as a treatment for acute ischaemic stroke. Stroke Phase 2 Clinical

Name	Amelparib
Synonyms	R252S84C2I Benzo[h][1,6]naphthyridin-5(1H)-one, 10-ethoxy-2,3,4,6-tetrahydro-8-(4-morpholinylmethyl)- Amelparib 10-Ethoxy-8-(4-morpholinylmethyl)-2,3,4,6-tetrahydrobenzo[h][1,6]naphthyridin-5(1H)-one

Description	Amelparib (JPI-289, JPI289) is a novel potent, water soluble PARP-1 inhibitor with IC50 of 18.5 nM, inhibits cellular PAR formation with IC50 of 10.7 nM; does not affect cell viability up to 1 mM in rat cortical neuronal cells; attenuates PARP activity restores ATP and NAD+ levels in oxygen glucose deprived (OGD) rat cortical neurons, reduces apoptosis-associated molecules such as apoptosis inducing factor (AIF), cytochrome C and cleaved caspase-3 in the OGD model; JPI-289 is a potential neuroprotective agent which could be useful as a treatment for acute ischaemic stroke. Stroke Phase 2 Clinical
References	References 1. Kim Y, et al. Clin Exp Pharmacol Physiol. 2017 Jun;44(6):671-679. 2. Kim Y, et al. Mol Neurobiol. 2018 Jan 30. doi: 10.1007/s12035-018-0910-6. View Related Products by Target PARP Stroke